Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates
- PMID: 33767591
- PMCID: PMC7975705
- DOI: 10.7150/ijbs.56214
Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates
Abstract
Nonalcoholic fatty liver disease (NAFLD) is leading chronic liver syndrome worldwide. Gut microbiota dysbiosis significantly contributes to the pathogenesis and severity of NAFLD. However, its role is complex and even unclear. Treatment of NAFLD through chemotherapeutic agents have been questioned because of their side effects on health. In this review, we highlighted and discussed the current understanding on the importance of gut microbiota, its dysbiosis and its effects on the gut-liver axis and gut mucosa. Further, we discussed key mechanisms involved in gut dysbiosis to provide an outline of its role in progression to NAFLD and liver cirrhosis. In addition, we also explored the potential role of probiotics as a treatment approach for the prevention and treatment of NAFLD. Based on the latest findings, it is evident that microbiota targeted interventions mostly the use of probiotics have shown promising effects and can possibly alleviate the gut microbiota dysbiosis, regulate the metabolic pathways which in turn inhibit the progression of NAFLD through the gut-liver axis. However, very limited studies in humans are available on this issue and suggest further research work to identify a specific core microbiome association with NAFLD and to discover its mechanism of pathogenesis, which will help to enhance the therapeutic potential of probiotics to NAFLD.
Keywords: Nonalcoholic fatty liver disease; dysbiosis; gut microbiota; nonalcoholic steatohepatitis; probiotics; small intestinal bacterial overgrowth..
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures



Similar articles
-
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 9. doi: 10.1007/s00210-025-04069-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40202676 Review.
-
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.J Cell Biochem. 2019 Mar;120(3):2713-2720. doi: 10.1002/jcb.27635. Epub 2018 Nov 15. J Cell Biochem. 2019. PMID: 30443932 Review.
-
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791767 Review.
-
Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.Clin Nutr ESPEN. 2021 Aug;44:61-68. doi: 10.1016/j.clnesp.2021.05.012. Epub 2021 May 25. Clin Nutr ESPEN. 2021. PMID: 34330514 Review.
-
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.World J Gastroenterol. 2014 Nov 14;20(42):15518-31. doi: 10.3748/wjg.v20.i42.15518. World J Gastroenterol. 2014. PMID: 25400436 Free PMC article. Review.
Cited by
-
Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction.Molecules. 2024 Feb 3;29(3):709. doi: 10.3390/molecules29030709. Molecules. 2024. PMID: 38338453 Free PMC article. Review.
-
Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention.Cells. 2022 Sep 10;11(18):2827. doi: 10.3390/cells11182827. Cells. 2022. PMID: 36139402 Free PMC article. Review.
-
The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases.Life (Basel). 2022 Aug 19;12(8):1263. doi: 10.3390/life12081263. Life (Basel). 2022. PMID: 36013442 Free PMC article. Review.
-
Diet-Regulating Microbiota and Host Immune System in Liver Disease.Int J Mol Sci. 2021 Jun 13;22(12):6326. doi: 10.3390/ijms22126326. Int J Mol Sci. 2021. PMID: 34199182 Free PMC article. Review.
-
Oxidative Stress, Gut Microbiota, and Extracellular Vesicles: Interconnected Pathways and Therapeutic Potentials.Int J Mol Sci. 2025 Mar 28;26(7):3148. doi: 10.3390/ijms26073148. Int J Mol Sci. 2025. PMID: 40243936 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical